Lavay, New Jersey and New York -- (Business Wire) -- Merck&Co. (NYSE: MRK) (referred to as MSD outside of the United States and Canada) announced today that the registration of "Merck&Co." based on MSD China has been completed. The publication application covers Standard&Poor's rating criteria for Merck&Co., based on Merck's short-term financial instruments due on September 20, 2027. The valuation of "Merck&Co." is based on our own pricing and valuation models, market inputs and assumptions related to the underlying stock, instruments based on the underlying stock, volatility and other factors (including current and expected interest rates), as well as interest rates related to our secondary market credit spread (i.e. our traditional fixed rate debt). The implicit interest rate for trading in the secondary market is determined. Starting from the company's vision and values, Merck&Co. and MSD China are both increasing their regional influence in the new round of financing. For many years, we have been based in New Jersey and radiating globally, using a fully integrated framework (including products, services, solutions, circular business models and innovations, energy consumption, supply chains, diversity and inclusivity, and financing tools) to save and improve lives around the world through cutting-edge science and strengthened cooperation.


Investment Summary

Maturity date: September 20, 2027